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activity of tigecycline against recent (2006) bacterial iso-
lates across Australia.
Methods: Non-duplicate strains were consecutively col-
lected from ﬁve medical centres in 5 states using isolates
from bacteraemia (n = 253), pneumonia (n = 146), compli-
cated skin and skin structure infections (n = 264), and
other infections (n = 269). All isolates were tested against
tigecycline using validated commercial reference broth
microdilution panels (TREK Diagnostics), with concurrent
quality controls and CLSI (M100-S18) interpretations for
comparison agents. Tigecycline breakpoints published by the
US-FDA were applied for each indicated species or genus
group.
Results: A total of 932 (268 Gram-negative and 664
Gram-positive) isolates were processed. Tigecycline was
highly active against the top 10 non-pseudomonal pathogens
which comprised 88% of all tested isolates. Tigecycline
MIC90 results ranged from ≤0.12 to 1mg/L, highest for
Klebsiella spp. and Proteae (data not shown). At US-FDA
published breakpoints, tigecycline exhibited complete inhi-
bition of indicated species except for a single strain of E.
cloacae (MIC, 4mg/L). Over 28% of Staphylococcus aureus
were oxacillin-resistant, and one Enterococcus faecium
was vancomycin-resistant. Tigecycline was highly effective
against these strains.
Conclusions: Tigecycline has potent activity against all
the common pathogens isolated in 2006 from Australian
patients, including those resistant to other drug classes.
Documented acquired resistance was rare among indicated
pathogens, however, Pseudomonas remains refractory to
potential tigecycline therapy.
doi:10.1016/j.ijid.2008.05.1083
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Objectives: Worldwide the prevalence of MDR Enter-
obacteriaceae are increasing, including ESBLs, AmpC,
ﬂuoroquinolone and carbapenem resistant strains. The
T.E.S.T. program determined the in vitro activity of tigecy-
cline compared to amoxicillin-clavulanic acid, piperacillin-
tazobactam, levoﬂoxacin, ceftriaxone, cefepime, ampi-
cillin, amikacin, minocycline, ceftazidime and imipenem
against Enterobacteriaceae species collected from hospi-
tals in Asia/Paciﬁc Rim 2004—2007. This study evaluated
the activity of tigecycline against multi-resistant microor-
ganisms associated with nosocomial infections.
Methods: A total of 2778 clinical isolates were identiﬁed
to the species level at each site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentration (MICs) were
determined by each site using supplied broth microdilution
panels and interpreted according to CLSI guidelines. Tigecy-
cline breakpoint is deﬁned as susceptible MICs ≤2mcg/mL
Results: The table illustrates the %S and MIC90 of tigecy-
cline to MDR pathogens
Conclusions: Multi-drug resistance is common in health
care acquired pathogens. The presented data indicate that
tigecycline is highly potent against nosocomial pathogens
including MDR isolates.
doi:10.1016/j.ijid.2008.05.1084
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Objectives: Tigecycline (TIG) is a new glycylcycline with
enhanced activity against many multidrug resistant (MDR)
pathogens including ESBL and AmpC producing Enterobacte-
riaceae, methicillin-resistant S. aureus (MRSA), carbapenem
resistant Acinetobacter and ﬂuoroquinolone resistant gram-
negative rods. The TEST study evaluated the activity of TIG
and comparators to pathogens in Canada 2004—2007.
Methods: A total of 1675 pathogens were collected from 8
participating sites in Canada from 2004—2007. Isolates were
identiﬁed to the species level and CLSI speciﬁed MICs were
performed at each site. CLSI or FDA breakpoints were used,
where applicable, to determine % susceptibility
Results: Tigecycline MICs are recorded in the table below
Conclusions: Tigecycline showed excellent in vitro activ-
ity against a diverse collection of pathogens isolated in
Canada between 2004—2007. MIC90 values of 0.5mcg/ml
against most Enterobacteriaceae including ESBL and MIC90
of ≤0.12mcg/ml against gram-positive pathogens document
the in vitro potency of tigecycline, a new glycylcycline.
doi:10.1016/j.ijid.2008.05.1085
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Aim: To assess the antimicrobial resistance patern in
pathogens responsible for urinary tract infections in noso-
comial patients over a period of one year.
Material and Method: From January 2006 to Decem-
ber 2006, 3665 urine cultures from nosocomial patients
were collected. All positive cultures with a colony count
≥105CFU/ml for Gram-positive and Gram-negative bacte-
ria and ≥103CFU/ml for Candida species were selected for
the analysis. Duplicate isolates were not considered
Results: Among the 757 positive cultures n = 135 belonged
to I.C.U., n = 58 to Surgical Dept, n = 347 to Internal Medicine
Dept and n = 217 to Outpatien Dept. Among the 757 pos-
itive cultures n = 523 belonged to female and n = 234 to
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male patients. Among the Gram-negative Escherichia coli
n = 337 presented the highest prevalence, followed by
Proteus mirabilis n = 97, Pseudomonas aeruginosa n = 67,
Candida species n = 65, Klebsiella pneumoniae n = 45 and
Acinetobacter baumannii n = 22. Among Gram positive iso-
lates Enterococcus faecalis was the most prevalence n = 28,
followed by coagulase negative staphylococci n = 16, Entero-
coccus faecium n = 11 and Staphylococcus aureus n = 5. They
were 4 VRE strains (Enterococcus faecium) in the urine. All
Gram positive cocci were sensitive to linezolide. Resistance
rates to Gram-negative are presented. All Gram-negative
were susceptible to colistin. All strains of Acinetobac-
ter baumannii were susceptible to doxycyclin while they
appeared susceptible to ampicillin/sulbactam to a percent-
age of 90%. The largest number of fungus positive samples
were taken from the Internal medicine departments
Conclusions: Escherichia coli is the primary bacterial
pathogen causing UTIs in nosocomial patients. Candida
albicans was isolated from the majority of the samples,
compared to non albicans.
doi:10.1016/j.ijid.2008.05.1086
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Purpose: The prescribing of quinolones in the outpa-
tient setting has resulted in widespread quinolone resistance
among gram-negative organisms. Because of this, quinolones
should no longer be used as empiric therapy in the manage-
ment of urinary tract infections within our hospitals. The
objectives of this study were to evaluate how educational
efforts would impact antimicrobial prescribing in the treat-
ment of urinary tract infections and whether the change
in prescribing habits would result in a change in bacterial
susceptibilities to quinolones within our hospitals.
Methods: Data was collected on all hospitalized patients
admitted with a diagnosis of urinary tract infections,
urosepsis, or pyelonephritis (n = 113) during January - May
2005. Antimicrobials selected for empiric and targeted
therapy were reviewed. Twenty-nine percent of community-
acquired infections and 41.2% of institutionally-acquired
infections were found to be resistant to the quinolones,
while only 15.6% and 17.1% of the respective infections
were resistant to cefazolin. The results were presented
to the Antibiotic Subcommittee of the Pharmacy & Thera-
peutics Committee, Emergency Medicine Department, and
hospitalists physician group. This was followed by an article
published in the physician newsletter on the management
of urinary tract infections. Empiric prescribing guidelines
encouraging the use of cefazolin were incorporated into
the system-wide antibiogram. Educational posters were
created and displayed at all of the nursing units and Emer-
gency Rooms. A follow-up study was conducted in January
- March 2007 (n = 75) to evaluate the impact of the educa-
tional efforts on antibiotic prescribing. Finally, the bacterial
susceptibilities were compared before and after the educa-
tional efforts.
Results: The empiric prescribing of quinolones for
the treatment of urinary tract infections, urosepsis, or
pyelonephritis decreased from 67.2% of patients in 2005
to 46.5% in 2007. The fraction of patients discharged on a
quinolone also decreased, 73% in 2005 to 47.7% in 2007. A
comparison of the 2005 to 2006 microbial data found that
there was a increase in the susceptibility of Pseudomonas
aeruginosa to quinolones from 65 -67% to 78% at PMC and
54% to 62% at POM, while there was no change in antimi-
crobial susceptibilities at PPH facilities that did not have an
educational program in place.
Conclusions: Educational efforts modestly improved the
selection of empiric antimicrobials in the treatment of
urinary tract infections at our community hospitals. Further-
more, the bacterial susceptibilities to the quinolones within
our hospitals improved.
doi:10.1016/j.ijid.2008.05.1087
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A 22-year-old male army ofﬁcer cadet presented with a
three day history of high fever, cough with haemoptysis,
sore throat, myalgia and severe diarrhoea. Investiga-
tions on admission showed a normal total white cell
count, hyponatraemia, a raised creatine kinase, pyuria
and a normal chest radiograph. He was administered oral
ciproﬂoxacin for three days with no resolution of fever
or symptoms. Repeat chest radiograph done on Day 4 of
admission showed multilobar pneumonia with worsening of
laboratory results. Antibiotic therapy was changed to intra-
venous penicillin, ceftazidime and azithromycin. His fever
and symptoms resolved promptly within 48 hours. Subse-
quent serological studies revealed a nine-fold increase in
Mycoplasma pneumoniae antibody titre, and the patient
was diagnosed with Mycoplasma pneumonia. Ciproﬂoxacin
is generally considered as an effective treatment against
Mycoplasma pneumoniae based on in-vitro susceptibility
to ciproﬂoxacin. Till date there has been only one case
report of its effective use (Masayoshi et al. Antibiotics and
Chemotherapy. 18(12), p1835—1839 Japanese). This case
report is the ﬁrst in the literature to suggest clinical fail-
ure. Ciproﬂoxacin may not be effective in the treatment of
Mycoplasma pneumonia.
doi:10.1016/j.ijid.2008.05.1088
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Background: It is a common knowledge that antibi-
otics are used indiscriminately. They should be used for
actual infections and not for colonization or prolonging the
